Loading...
-
Enterin is aiming to become the first company
in the world to develop a novel drug thatrepairs the
dysfunctional
gut-brain axisin patients with neurodegenerative disease.In preclinical models of Parkinson's Disease,ENT-01 displaces
a-synuclein aggregatesand restores normal signaling between the gut and the brain.Our lead molecule, ENT-01,has recently met it's
primary endpointin a Phase 2b study for patients with Parkinson's Disease.Our clinical data indicates that
repair the gut-brain axis is able tosignificantly improve
quality of lifeby influencing multiple non-motor symptoms that affect patients with
Parkinson's Disease and other neurodegenerative conditions.